Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Sequencing impact and prognostic factors in metastatic castration-resistant prostate cancer patients treated with cabazitaxel: A systematic review and meta-analysis

Published:2023-04 Issue:4 Volume:41 Page:177-191
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Yanagisawa Takafumi^ORCID,Kawada Tatsushi,Rajwa Pawel,Mostafaei Hadi,Motlagh Reza Sari,Quhal Fahad,Laukhtina Ekaterina,König Frederik,Pallauf Maximilian,Pradere Benjamin,Karakiewicz Pierre I.,Nyirady Peter,Kimura Takahiro,Egawa Shin,Shariat Shahrokh F.

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference59 articles.

1. NCCN guidelines insights: prostate cancer, version 1.2021;Schaeffer;J Natl Compr Canc Netw,2021

2. Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial;Gravis;Eur Urol,2016

3. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer;Sweeney;N Engl J Med,2015

4. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol;Sydes;Ann Oncol,2018

5. Androgen receptor on the move: boarding the microtubule expressway to the nucleus;Thadani-Mulero;Cancer Res,2012

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabrication of co-delivery liposomal formulation incorporating carmustine and cabazitaxel displays improved cytotoxic potential and induced apoptosis in ovarian cancer cells;Journal of Biomaterials Science, Polymer Edition;2024-08-29

2. A vitamin D‐based strategy overcomes chemoresistance in prostate cancer;British Journal of Pharmacology;2024-07-09

3. Construction of cabazitaxel-loaded nanocellulose-clocked mesoporous organosilica nanoparticles for enhanced lung cancer therapy;Process Biochemistry;2024-07

4. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE);ESMO Open;2024-05

5. A net-work meta-analysis of the cardiac safety for next-generation hormonal agents in treating castration-resistant prostate cancer: How to choose drugs appropriately?;Critical Reviews in Oncology/Hematology;2024-04